Three Post-Approval Changes in One Cycle: Variation or New Application?
Medipro Ltd, a Nairobi manufacturer, holds a marketing authorisation for Cefrine 500 mg film-coated tablets, shelf life 24 months, packed in PVC/Alu blisters. In a single submissions cycle it wants to: (1) move only the film-coating step to a second licensed site 40 km away, keeping granulation and compression at the original site; (2) extend shelf life from 24 to 36 months using 12 months' long-term and 6 months' accelerated stability data; (3) add a 250 mg strength made from the same granulate, with tablet weight halved, intended for paediatric use and carrying a weight-based paediatric dose statement that does not appear on the 500 mg label. Stock of the 500 mg with 24-month expiry is already in wholesalers. The company asks whether it can start printing 36-month expiry dates next month and ship the 250 mg as soon as the tablets are packed and tested.
1. Classify each of the three proposed changes: which require a variation and which require a new marketing authorisation? State the test you applied and the evidence that drives each classification.
Read the worked answer
Apply a two-part test to each change: does it alter the evidence of quality, safety or efficacy on which the authorisation was granted, and does the current PPB variation guideline name it as a recognised variation category? A change that is named and for which comparability can be demonstrated is a variation; a change that alters the product identity or the basis of the benefit-risk decision needs a new application.
1. Film-coating site transfer. Same MA holder, same composition, same specification, one manufacturing step relocated to a site that already holds a manufacturing licence. This is a site-change variation, normally major, because coating affects dissolution and appearance. Evidence: process validation/PPQ at the receiving site, comparative dissolution across the standard pH media, batch analysis, short-term stability, updated site master file and evidence of GMP status at the new site. It is not a new MA because comparability can be shown and nothing about the product's identity changes.
2. Shelf life 24 to 36 months. A variation supported by stability data. Twelve months' long-term plus six months' accelerated is workable only if there is no significant change at accelerated conditions and no failing trend at long-term. Extrapolation beyond the period covered is governed by the guideline's extrapolation rules and is not automatic. If the data are clean, 36 months with an ongoing stability commitment is defensible; if there is any significant change, a shorter extension (for example 30 months) is the correct outcome.
3. 250 mg strength. An additional strength of the same immediate-release formulation is usually handled as an extension variation, but only where dose proportionality of the granulate and comparative dissolution justify a biowaiver. If proportionality fails, or if a new paediatric indication is being claimed, treat it as a new application with bioequivalence data or a formal biowaiver justification.
2. What must be true before the company may print 36-month expiry dates, and what conditions would you attach?
Read the worked answer
The 36-month date may not be printed until the shelf-life variation is approved; the approved dossier currently states 24 months. Printing an unapproved expiry is a labelling falsification issue, not a commercial shortcut, and the batches already in wholesalers must keep their 24-month expiry. Re-labelling existing stock is not acceptable - the cartons were released against the 24-month shelf life and any over-labelling destroys batch traceability.
Once approved, the conditions would be: the extension applies only to batches manufactured after the approval date and within the validated process; at least one production batch per year enters the long-term stability programme and is followed to 36 months, with annual reporting of data; any out-of-specification result or significant change on a stability batch must be notified immediately, because the extrapolation rests on the assumption that the long-term trend is stable; any further extension beyond 36 months needs a new submission; and the commitment should cover the 250 mg strength separately once that strength is authorised, since it is a different tablet weight and may behave differently.
3. The 250 mg tablets will carry a weight-based paediatric dose statement absent from the 500 mg label. How does that affect your decision, and what labelling risks do you flag?
Read the worked answer
A strength addition that also introduces paediatric dosing is not a purely administrative extension. Two questions decide the route. First, is the new dose statement a new indication or posology requiring its own benefit-risk assessment? If yes, it is a major variation at minimum and plausibly a new application. Second, is the 250 mg genuinely interchangeable with the 500 mg on a per-milligram basis? If dissolution and proportionality support it, the strength can be an extension, but the paediatric posology still needs supporting data (a PK or literature-based justification, and a suitable dosing device or scored tablet if fractions are needed).
The labelling risks are concrete. Two strengths of the same brand in similar packaging invite selection errors, and a halved tablet weight with identical appearance makes visual differentiation impossible; require distinct colour, embossing or pack design, and tall-man lettering on the carton. The 500 mg label must not continue to imply paediatric use if that claim now belongs only to the 250 mg, or the two labels contradict each other. The dose statement must state mg/kg with an upper limit and a maximum daily dose, because weight-based dosing without a ceiling is a recognised source of overdose in children. Finally, check that the patient information leaflet, the summary of product characteristics and the pack are updated together; a mismatch between carton and leaflet is itself a defect.